Standardise
the methodology
Further develop defined pre-analytical procedures and uniform measurement conditions.
Innovation
Innovation
that moves us forward.
The patented core technology opens up new perspectives for analysis, data processing and future diagnostic systems.
On a scientific foundation
Technological core
Precision through
development.
The developed assay is the starting point. Its further development combines defined measurement conditions with analytical testing and transfer to standardised technical systems.
Protein-optical assayDeveloped foundation
Standardise
Investigate
robustness
Assess reproducibility, analytical stability and potential influencing factors.
Validate
Delta
Further develop and validate photometric difference calculation under two measurement conditions.
Transfer to
technical systems
Further develop the measurement methodology for standardised technical measurement systems.
Scientific evidence
Building
on results.
The blood-test technology has been investigated in two external studies and one internal Delta evaluation. The results provide a scientific foundation for the next development steps.
861
Cases and samples examined
in three scientific evaluations
Two external studies.
One internal Delta evaluation.
External
Salat cohort
External
Walter et al.
Internal
Delta evaluation
Prospective studies & clinical development
The next steps.
Prospective studies.
Building on the results to date, CARCIMUN is preparing further prospective clinical studies. The necessary development work has already been initiated. The focus is on clearly defined scientific questions and systematic validation of the intended applications.
Prospective studies in preparation
01Cancer
Cancer
monitoring
The longitudinal application of CARCIMUN technology is intended to make individual changes in the course of cancer traceable through repeated blood measurements and a personal baseline. Notable deviations are intended to be made available promptly to the treating care team as additional indications of possible changes in tumour activity – including between routine follow-up imaging examinations. The clinical performance of this approach is to be validated in prospective studies.
02
Treatment support
The aim is to enable patients to take regular measurements even after returning home. The results are compared with a previously established individual baseline. Where defined deviations occur, the treating care team is intended to be notified automatically so that notable changes can be assessed clinically without delay. This application concept is to be validated in prospective studies.
03
HealthMarker
Prospective studies are intended to investigate whether regular blood tests help detect changes in an individual's health status at an early stage. In the future, this approach could complement existing longevity systems with an additional, specific blood-test and longitudinal monitoring component, opening up new possibilities for individual health guidance.
Further study concepts · preparation and approval process
New clinical questions.
pulmonary nodules
requiring further assessment
CARCIMUN aims to use the patented blood-test technology in the future for indeterminate pulmonary nodules and mammography findings requiring further assessment. By providing a more precise assessment of whether cancer might be present, the aim is to support more targeted medical decisions and, where possible, avoid unnecessary biopsies or surgical procedures.
The required approvals are currently being processed. Once they have been granted, the corresponding studies are to be conducted and scientific and clinical validation undertaken.
AI & Data
Connecting data.
Understanding change.
Repeated measurements open up a temporal perspective. Individual baselines are intended to help describe changes relative to a person's starting point.
CARCIMUN is already further developing this analytical function with partners in AI & Data. The focus is on assessing AI-assisted methods that could interpret individual changes relative to a personal baseline and, in the future, link them with further medical and health-related information.
Miniaturisation
Smaller systems.
New possibilities.
The existing laboratory technology provides the foundation for long-term development towards miniaturised measurement systems. Microchip technology, compact readout systems and digital analysis are intended to be brought together. One aim is to create the conditions for future decentralised and point-of-care applications.
01 / MeasurementMicrochip-based
Microchip-based
technology
02 / SystemCompact
Compact
readout systems
03 / Application outlookDecentralised measurement.
Decentralised measurement.
Digitally connected.
Molecular biology research
New perspectives
at the molecular level.
Complementary molecular biological approaches broaden the scientific view of biological relationships. They form a distinct line of research within the platform's long-term development.
The research explores potential foundations for additional scientific and technological developments and future diagnostic methods.
Development at a glance
A clear foundation.
Several next steps.
Existing
technological foundation
Protein-optical assay and scientific evaluations to date.
Further development
and validation
Delta validation, standardisation, analytical robustness and further prospective studies.
Technological and clinical
development perspectives
AI & Data, monetisation of digital analytical services, miniaturisation and future decentralised measurement systems, as well as applications for indeterminate pulmonary nodules and mammography findings requiring further assessment that are to be investigated prospectively.
Early research
Molecular biological approaches for potential extensions of the platform.
Scientific insights.
Technological advancement.